KCM Investment Advisors LLC Increases Position in Boston Scientific Corporation $BSX

KCM Investment Advisors LLC lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 9.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,930 shares of the medical equipment provider’s stock after purchasing an additional 876 shares during the period. KCM Investment Advisors LLC’s holdings in Boston Scientific were worth $1,067,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BSX. Harvest Portfolios Group Inc. lifted its position in shares of Boston Scientific by 1.1% during the 2nd quarter. Harvest Portfolios Group Inc. now owns 549,602 shares of the medical equipment provider’s stock valued at $59,033,000 after acquiring an additional 6,234 shares during the period. Nvwm LLC raised its holdings in Boston Scientific by 24,602.4% during the second quarter. Nvwm LLC now owns 10,128 shares of the medical equipment provider’s stock worth $1,088,000 after purchasing an additional 10,087 shares during the last quarter. Savant Capital LLC boosted its position in Boston Scientific by 4.1% during the second quarter. Savant Capital LLC now owns 21,236 shares of the medical equipment provider’s stock worth $2,281,000 after purchasing an additional 834 shares in the last quarter. Valtinson Bruner Financial Planning LLC acquired a new stake in Boston Scientific in the second quarter valued at $201,000. Finally, Headland Capital LLC increased its position in shares of Boston Scientific by 1.6% in the second quarter. Headland Capital LLC now owns 89,704 shares of the medical equipment provider’s stock valued at $9,635,000 after buying an additional 1,441 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on BSX. Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. Wells Fargo & Company increased their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. UBS Group raised their price objective on shares of Boston Scientific from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Evercore ISI restated an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $123.77.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at $17,739,678.74. The trade was a 21.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 175,782 shares of company stock worth $17,742,314. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Up 1.0%

Shares of NYSE BSX opened at $100.05 on Friday. The firm has a market cap of $148.32 billion, a P/E ratio of 53.50, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50. The firm’s 50 day moving average price is $100.09 and its 200 day moving average price is $102.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The business’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.